Parkinson's disease: Is the initial treatment established?

Current Neurology and Neuroscience Reports

Volumn 3, Issue 4, 2003, Pages 289-295

  Ahlskog, J Eric ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; EDEMA; HALLUCINOSIS; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REGULATORY MECHANISM; REVIEW; RISK REDUCTION; SOMNOLENCE; TIME; ANIMAL; DRUG COMBINATION; METABOLISM; STATISTICS;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0141610593     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-003-0005-1     Document Type: Review

References (41)

1. Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
2. Apaydin H, Ahlskog JE, Parisi JE, et al.: Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002, 59:102-112.
3. Olanow CW: Oxidation reactions in Parkinson's disease. Neurology 1990, 40:32-37.
4. Fahn S, Cohen G: The oxidant stress hypothesis in Parkinson's disease: evidence supporting it [review]. Ann Neurol 1992, 32:804-812.
5. Ahlskog JE: Parkinson's disease: medical and surgical treatment. Neurol Clin 2001, 19:579-605.
6. Agid Y, Ahlskog E, Albanese A, et al.: Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 1999, 14:911-913.
7. Schrag A, Ben-Shlomo Y, Brown R, et al.: Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 1998, 13:885-894.
8. Muenter MD, Ahlskog JE: Dopa dyskinesias and fluctuations are not related to dopa treatment duration. Ann Neurol 2000, 48:464.
9. Mizuno Y, Kondo T, Narabayashi H: Pergolide in the treatment of Parkinson's disease. Neurology 1995, 45:S13-S21.
10. Rinne UK, Bracco F, Chouza C, et al.: Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 1998, 55:23-30.
11. Rascol O, Brooks D, Korczyn AD, et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484-1491.
12. Parkinson Study Group: A randomized controlled trial comparing the agonist pramipexole with levodopa as initial dopaminergic treatment for Parkinson's disease. JAMA 2000, 284:1931-1938.
13. Whone AL, Remy P, Davis MR, et al.: The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with l-dopa. Neurology 2002, 58:A82-A83.
14. Holloway RG, for the Parkinson Study Group: Pramipexole versus levodopa as initial treatment for Parkinson disease: a four-year randomized controlled trial. Neurology 2002, 58:A81-A82.
15. Uitti RY, Ahlskog JE: Comparative review of dopamine receptor agonists in Parkinson's disease. Cent Nerv Syst Drugs 1996, 5:369-388.
16. Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653-1661.
17. Kimmel HL, Joyce AR, Carroll FI, Kuhar MJ: Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. J Pharmacol Exp Ther 2001, 298:129-140.
18. Lee CS, Samii A, Sossi V et al.: In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000, 47:493-503.
19. Uhl GR, Walther D, Mash D, et al.: Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 1994, 35:494-498.
20. Harrington KA, Augood SJ, Kingsbury AL, et al.: Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease. Brain Research. Mol Brain Res 1996, 36:157-162.
21. Joyce JN, Smutzer C, Whitty CJ, et al.: Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Mov Disord 1997, 12:885-897.
22. Zhang L, Coffey LL, Reith ME: Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem Pharmacol 1997, 53:677-688.
23. Vaughan RA, Huff RA, Uhl GR, Kuhar MJ: Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem 1997, 272:15541-15546.
24. Pristupa ZB, McConkey F, Liu F, et al.: Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 1998, 30:79-87.
25. Meiergerd SM, Patterson TA, Schenk JO: D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 1993, 61:764-767.
26. Batchelor M, Schenk JO: Protein kinase A activity may kinetically upregulate the striatal transporter for dopamine. J Neurosci 1998, 18:10304-10309.
27. Guttman M, Stewart D, Hussey D, et al.: Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001, 56:1559-1564.
28. Ahlskog JE, Uitti RJ, O'Connor MK, et al.: The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999, 14:940-946.
29. Innis RB, Marek KL, Sheff K, et al.: Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 1999, 14:436-442.
30. Nurmi E, Bergman J, Eskola O, et al.: Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab 2000, 20:1604-1609.
31. Ballard PA, Tetrud JW, Langston JW: Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985, 35:949-956.
32. Cromwell WC, Ziajka PE: Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. Am J Cardiol 2000, 86:1123-1127.
33. Locatelli S, Lutjohann D, Schmidt HH, et al.: Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia. Evidence that simvastatin affects cholesterol metablism in the human brain. Arch Neurol 2002, 59:213-216.
34. Torstenson R, Hartvig P, Langstrom B, et al.: Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol 1997, 41:334-340.
35. Ekesbo A, Rydin E, Torstenson R, et al.: Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 1999, 52:120-125.
36. Knudsen GM, Hasselbalch S, Toft PB, et al.: Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. J Inherited Metab Dis 1995, 18:653-664.
37. Boomsma F, Meerwaldt JD, Man in't Veld AJ, et al.: Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. J Neurol 1989, 236:223-230.
38. Ward CD, Trombley IK, Calne DB, Kopin IJ: L-dopa decarboxylation in chronically treated patients. Neurology 1984, 34:198-201.
39. Durso R, Evans JE, Josephs E, et al.: Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol 2000, 40:854-860.
40. Frucht S, Rogers JD, Greene PE, et al.: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexote and ropinirole. Neurology 1999, 52:1908-1910.
41. Miyasaki JM, Martin W, Suchowersky O, et al.: Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002, 58:11-17.